SynerGNet: A Graph Neural Network Model to Predict Anticancer Drug Synergy

Author:

Liu Mengmeng1ORCID,Srivastava Gopal2,Ramanujam J.13ORCID,Brylinski Michal23ORCID

Affiliation:

1. Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA 70803, USA

2. Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA

3. Center for Computation and Technology, Louisiana State University, Baton Rouge, LA 70803, USA

Abstract

Drug combination therapy shows promise in cancer treatment by addressing drug resistance, reducing toxicity, and enhancing therapeutic efficacy. However, the intricate and dynamic nature of biological systems makes identifying potential synergistic drugs a costly and time-consuming endeavor. To facilitate the development of combination therapy, techniques employing artificial intelligence have emerged as a transformative solution, providing a sophisticated avenue for advancing existing therapeutic approaches. In this study, we developed SynerGNet, a graph neural network model designed to accurately predict the synergistic effect of drug pairs against cancer cell lines. SynerGNet utilizes cancer-specific featured graphs created by integrating heterogeneous biological features into the human protein–protein interaction network, followed by a reduction process to enhance topological diversity. Leveraging synergy data provided by AZ-DREAM Challenges, the model yields a balanced accuracy of 0.68, significantly outperforming traditional machine learning. Encouragingly, augmenting the training data with carefully constructed synthetic instances improved the balanced accuracy of SynerGNet to 0.73. Finally, the results of an independent validation conducted against DrugCombDB demonstrated that it exhibits a strong performance when applied to unseen data. SynerGNet shows a great potential in detecting drug synergy, positioning itself as a valuable tool that could contribute to the advancement of combination therapy for cancer treatment.

Funder

Center for Computation and Technology at Louisiana State University

Publisher

MDPI AG

Reference55 articles.

1. Hallmarks of cancer: The next generation;Hanahan;Cell,2011

2. Timeline: Chemotherapy and the war on cancer;Chabner;Nat. Rev. Cancer,2005

3. Targeted Cancer Therapies;Smith;Am. Fam. Physician,2021

4. Cancer immunotherapy;Baxevanis;Crit. Rev. Clin. Lab. Sci.,2009

5. Cancer drug resistance: An evolving paradigm;Holohan;Nat. Rev. Cancer,2013

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3